Tirapazamine (TPZ) with conventional trans-arterial chemoembolization had a good safety profile and promising efficacy signals in early- and intermediate-stage liver cancer, including in patients who had progression or recurrence after standard therapy
Of the 17 evaluable patients, including 10 who progressed despite prior therapy, 47% achieved complete response, with a median time to progression of 12.6 months and a median overall survival of 29.3 months
Results are consistent with the response rates seen in previous treatment-naive patient cohort, and support the theory that TPZ chemoembolization could induce complete tumor necrosis
The dose was selected for a randomized Phase 2 study to compare TPZ with doxorubicin, a current therapy, using the same embolization protocol
PRINCETON, N.J., and TAIPEI, Taiwan, June 21, 2022 (GLOBE NEWSWIRE) -- Teclison, a clinical-stage biotechnology company developing innovative cancer therapeutics to induce tumor necrosis and enhance anti-tumor immunity, today announced the peer-reviewed publication of a study demonstrating the safety, tolerability and preliminary efficacy of its trans-arterial tirapazamine chemoembolization (TATE) therapy in patients with unresectable early- and intermediate-stage hepatocellular carcinoma (HCC), also known as liver cancer. The clinical data, published in The Journal of Vascular and Interventional Radiology titled Phase I Dose-Escalation Study of Tirapazamine Chemoembolization for Unresectable Early- and Intermediate-Stage Hepatocellular Carcinoma, establishes tirapazamine, a hypoxia-activated anti-cancer drug, as safe when administered in conjunction with trans-arterial embolization with promising efficacy in patients with liver cancer, including those with progression or recurrence after treatment with conventional trans-arterial chemoembolization (TACE).
The current standard of care for unresectable liver cancer is conventional trans-arterial chemoembolization with the chemotherapeutic agent doxorubicin. Though well established, TACE with doxorubicin has limited efficacy because chemotherapy does not effectively kill cancer stem cells, a root cause for tumor recurrence after TACE. Additionally, embolization-induced tumor hypoxia is thought to dampen the cytotoxic effects of doxorubicin, said Chang-Hsien Liu, MD, principal investigator of the study. The results of this study support tirapazamine as an alternative to doxorubicin in trans-arterial chemoembolization. A future randomized study is warranted to compare tirapazamine and doxorubicin under embolization.
Ray Lee, MD, PhD, Founder and CEO of Teclison, added, We are encouraged by the potential of trans-arterial tirapazamine chemoembolization to improve the clinical response and extend overall survival when administered to patients with liver cancer. This data reinforces findings from our previous first-in-human study published in the Journal of Hepatocellular Carcinoma and establishes the tirapazamine dose for subsequent Phase 2 clinical trials.
Seventeen patients with unresectable early-stage HCC or unresectable intermediate-stage HCC were enrolled in this non-randomized, open-label Phase 1 study. Prior treatment such as surgery, radiofrequency ablation, and TACE, was permitted. Following a 3 + 3 dose escalation design, patients were assigned to three cohorts with a tirapazamine dose of 5mg/m2, 10mg/mg2 and 20mg/m2, respectively. As no dose-limiting toxicity was observed, the 20mg/m2 dose was converted to a fixed 35mg dose in the expansion cohort. The primary outcomes of the study were safety and tolerability. No serious adverse side effect was reported during the study. Most common adverse effects included transiently elevated liver enzymes, abdominal pain, fever, elevated bilirubin level, and transient ECG abnormality. The secondary endpoint was efficacy of TATE therapy. Of the 17 enrolled patients, 8 achieved complete response (CR 47.1%) as measured radiographically. Three patients achieved a partial response (PR 17.6%) for an overall response rate of 65%. CR rates were comparable between subgroups with and without prior TACE. The six-month progression-free survival rate was 72.6% and the median overall survival (OS) was 29.3 months.
Trans arterial chemoembolization (TACE) is the common therapeutic modality recommended by the Barcelona Clinic Liver Cancer (BCLC) staging system for patients with intermediate or advanced HCC. The overall response rate of TACE is 52% and median OS of about 20 months in a recent systemic review of 10,000 patients. A Phase 2 randomized study comparing efficacy of TATE vs TACE in patients with intermediate liver cancer is underway.
About TeclisonTeclison is a clinical-stage pharmaceutical company developing novel cancer therapeutics to induce targeted necrosis of solid tumors and convert the tumor into a therapeutic vaccine to enhance cancer remission. The Companys portfolio is comprised of new approaches aimed at enhancing the therapeutic benefit of immunotherapy to treat nearly all solid tumors. Its lead product candidate, TEC-001, a first-in-class therapeutic agent, and Trans-Arterial TEC-001 Embolization (TATE) therapy, are being evaluated in combination with FDA-approved immune checkpoint inhibitors in Phase 2 clinical trials for the treatment of liver, colorectal and lung cancer. Teclison is headquartered in Princeton, New Jersey. For more information, please visitwww.teclison.com.
Forward-Looking StatementsThis press release contains statements that are forward-looking statements that are based upon managements current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated herein.
Media contact:Gloria GasaaturaLifeSci CommunicationsTel: (646) 970-4688ggasaatura@lifescicomms.com
Read more from the original source:
Teclison Announces Publication of Phase 1 Data Demonstrating the Safety and Therapeutic Potential of Tirapazamine Chemoembolization for Patients with...
- Latest Insights on Stem Cell Assay Market Business Strategies, Acquisitions, Revenue Analysis Share, Forecast to 2028 | by Perkinelmer Inc, Promega... - October 13th, 2022
- S.I. school hosts dance-a-thon to support 9-year-old student with sickle cell disease - SILive.com - October 13th, 2022
- Cord blood bank - Wikipedia - October 4th, 2022
- Cell Reprogramming Market is Expected to Record the Massive Growth, with Prominent Key Players Allele Biotechnology, ALSTEM, Applied Biological... - September 16th, 2022
- Pleco Therapeutics Announces Final Close of its Series A Financing Raising 17.3m to Progress its Novel Plecoid Product in Acute Myeloid Leukaemia to... - September 8th, 2022
- Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates - KULR-TV - August 14th, 2022
- Cell Expansion Market Size, Scope, Growth Opportunities, Trends by Manufacturers And Forecast to 2029 Shanghaiist - Shanghaiist - August 5th, 2022
- 3D Bioprinting for Tissue and Organ Regeneration Market worth $424.3 Million by 2030 - Exclusive Report by InsightAce Analytic - Yahoo Finance - July 27th, 2022
- After conquering sickle cell and multiple sclerosis, it was COVID-19 that claimed her - Lynchburg News and Advance - July 11th, 2022
- Stem Cell Therapy Market to Observe Exponential Growth By 2022 to 2030 | Smith, Nephew (UK), MEDIPOST Co Ltd. (South Korea) - Digital Journal - June 22nd, 2022
- This Key Protein Is Essential for Brain Cell Longevity and Growth - SciTechDaily - June 13th, 2022
- Stem Cell Cartilage Regeneration Market to Witness Massive Growth from 2022 to 2030 | Central members covered as a piece of this study incorporate... - June 13th, 2022
- Stem Cell Therapy Market Size, Scope and Forecast | Osiris Therapeutics Medipost Co. Ltd., Anterogen Co. Ltd., Pharmicell Co. Ltd.,... - June 4th, 2022
- Advanced Therapy Medicinal Products (ATMP) Service Providers Market worth $34.59 Billion by 2030 - Exclusive Report by InsightAce Analytic - Yahoo... - June 4th, 2022
- Gene Therapy Market Size, Scope and Forecast | Novartis AG, Biogen, Gilead Sciences MolMed SpA, Spark Therapeutics Orchard Therapeutics plc., SIBIONO,... - June 4th, 2022
- Cell Isolation/Cell Separation Market Size, Scope and Forecast | Beckman Coulter (Subsidiary of Danaher Corporation), Becton, Dickinson and Company,... - June 4th, 2022
- 8 Players Leading the 3D Printed Meat Revolution - 3DPrint.com - May 2nd, 2022
- Penn researchers discover new cell type in human lung with regenerative properties - EurekAlert - April 6th, 2022
- FDA Grants Fast Track Designation to CYNK-001 for AML Treatment - Targeted Oncology - January 5th, 2022
- Stem Cell Therapy: a Look at Current Research, Regulations ... - December 24th, 2021
- Stem Cells Market to Witness Gigantic Growth by 2026 LSMedia - LSMedia - December 24th, 2021
- Peaceful Protest at Cherry Hill Women's Center Warning Public of Increase in Late Term Abortions In New Jersey. - InsiderNJ - October 16th, 2021
- Time to Go Sushi With Cellular Salmon; When Pet Owners Tire of Their Minions - The SandPaper - August 18th, 2021
- Avalon GloboCare, UPMC Hillman and University of Pittsburgh to develop new cancer immunotherapy - Proactive Investors USA & Canada - August 5th, 2021
- John Theurer Cancer Center Investigators Participated in ZUMA-7 Study Showing Value of CAR T-Cell Therapy as Second-Line Treatment for Relapsed Large... - July 21st, 2021
- ExoFlo From Direct Biologics Fulfills Urgent Medical Need in COVID-19 Treatment - PRNewswire - July 21st, 2021
- GXGX Merger: The SPAC News That Has GXGX Stock Soaring - InvestorPlace - July 21st, 2021
- This Startup is Changing the Way Spinal Cord Injury Is Treated Around the World - Entrepreneur - June 23rd, 2021
- Genmab Announces that Janssen has Received European - GlobeNewswire - June 23rd, 2021
- Gene therapy offers potential cure to children born without an immune system - UCLA Newsroom - May 13th, 2021
- Commencement stories from Rowan paint a picture of opportunities near and far - NJ.com - May 13th, 2021
- Vitalant to Hold Blood Donation Event on December 5 in Freehold - TAPinto.net - December 1st, 2020
- Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn - GlobeNewswire - October 23rd, 2020
- Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma... - October 23rd, 2020
- Novel Strategies for Targeting the Guardian of the Genome Emerge - OncLive - October 23rd, 2020
- CRISPR Market to See Massive Growth by 2026 | GE Healthcare Dharmacon, CRISPR Therapeutics, Thermo Fisher Scientific - Aerospace Journal - October 23rd, 2020
- Smith's 2005 stem cell law to be reauthorized by House - InsiderNJ - October 4th, 2020
- Oakland 24-year-old seeking multiethnic bone marrow donor - The Jewish News of Northern California - September 21st, 2020
- 99-million-year-old fight between hell ant and its prey preserved in amber - BBC Focus Magazine - August 12th, 2020
- Vitalant to Hold Blood Donation Drive on August 11 in Atlantic Highlands - TAPinto.net - August 12th, 2020
- Stem Cells Sales Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News - July 7th, 2020
- Mesenchymal Stem Cells Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News - July 7th, 2020
- Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market 2019 Break Down by Top Companies, Countries, Applications, Challenges,... - June 10th, 2020
- Stem Cells Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast 2026 - Cole of Duty - June 10th, 2020
- Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX (daratumumab) for the Treatment of Patients with... - June 10th, 2020
- CO2 Incubators Market is Expected to Witness a Steady Growth by 2025 - Farmers Ledger - June 4th, 2020
- Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma GmbH Enter into Strategic Clinical and Commercial Manufacturing Agreements with... - May 13th, 2020
- Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), for the Treatment... - May 6th, 2020
- CO2 Incubators Market Update: Uncover the Business Strategies of Leaders & Laggards of the Market - 3rd Watch News - March 6th, 2020
- SpaceX set to launch Falcon 9 rocket and Dragon capsule from Cape Canaveral this week - Florida Today - March 4th, 2020
- Are stem cells really the key to making humans live longer? - Wired.co.uk - February 16th, 2020
- Musicians and community coming together in Asbury Park to help Point Pleasant 3-year old - Asbury Park Press - February 12th, 2020
- TV Guy: A return to history with Auschwitz Untold - New Jersey Herald - January 27th, 2020
- Europe's guardian of stem cells and hopes, real and unrealistic - FRANCE 24 - January 20th, 2020
- Horizon Discovery to Provide Access to Novel Base Editing Technology - Yahoo Finance - January 15th, 2020
- John Theurer Cancer Center Announces Appointment of Five New Physicians - Newswise - January 15th, 2020
- Horizon to provide access to novel base editing technology - SelectScience - January 15th, 2020
- Reviewing Phibro Animal Health (NASDAQ:PAHC) & AgeX Therapeutics (NASDAQ:AGE) - Riverton Roll - January 15th, 2020
- Stemming the Tide Confronting Anti-Semitism in the 21st Century - The Times of Israel - January 5th, 2020
- Weekly pick of Neuroscience news from around the world - Brain Tumour Research - November 30th, 2019
- Comparing of Rigel Pharmaceuticals Inc. (RIGL) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - The Broch Herald - November 28th, 2019
- Celgene to Present New and Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annual Meeting - Business... - November 6th, 2019
- Reviewing Surface Oncology Inc. (SURF)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - FinanceMercury - November 6th, 2019
- Reviewing Magenta Therapeutics Inc. (MGTA)'s and PTC Therapeutics Inc. (NASDAQ:PTCT)'s results - FinanceMercury - November 6th, 2019
- Reviewing Capricor Therapeutics Inc. (CAPR)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - FinanceMercury - November 6th, 2019
- Live Cell Imaging Consumables Market Evolving to a Next-Generation Strategy with New Partnerships, Technologies and Targets by 2023 key players LCC... - November 6th, 2019
- Contrasting of Spero Therapeutics Inc. (SPRO) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - FinanceMercury - November 6th, 2019
- PTC Therapeutics Inc. (PTCT) and Jounce Therapeutics Inc. (NASDAQ:JNCE) Comparing side by side - FinanceMercury - November 6th, 2019
- Contrasting of Brainstorm Cell Therapeutics Inc. (BCLI) and HOOKIPA Pharma Inc. (NASDAQ:HOOK) - MS Wkly - November 2nd, 2019
- Reviewing Brainstorm Cell Therapeutics Inc. (BCLI)'s and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)'s results - MS Wkly - November 2nd, 2019
- Reviewing ImmunoGen Inc. (IMGN)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly - November 2nd, 2019
- On Stage: Allegaeon ready to rock Philly - The Unionville Times - November 2nd, 2019
- Comparison of Merus N.V. (MRUS) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - MS Wkly - October 14th, 2019
- Reviewing Curis Inc. (CRIS)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly - October 14th, 2019
- Comparing of NewLink Genetics Corporation (NLNK) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - MS Wkly - October 14th, 2019
- Reviewing Morphic Holding Inc. (MORF)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly - October 14th, 2019
- Reviewing PTC Therapeutics Inc. (PTCT)'s and Inovio Pharmaceuticals Inc. (NASDAQ:INO)'s results - MS Wkly - October 14th, 2019
- Comparing of Osmotica Pharmaceuticals plc (OSMT) and VistaGen Therapeutics Inc. (NASDAQ:VTGN) - MS Wkly - October 14th, 2019
- PTC Therapeutics Inc. (PTCT) and MacroGenics Inc. (NASDAQ:MGNX) Comparing side by side - MS Wkly - October 14th, 2019
- Obtain Stem Cell Therapy in New Jersey - Stem Cell Miami - February 23rd, 2019